Andere Sprachen Cidara Therapeutics, Inc.

Aktien

A3D4A6

US1717572069

CDTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
12.63 ^USD	-2.85%		-7.27%	-20.47%

25.04.	Top Premarket Gainers	MT
24.04.	Transcript : Cidara Therapeutics, Inc. - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024	26.04.
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX	25.04.
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE	25.04.
Top Premarket Gainers	25.04.
North American Morning Briefing : More Tech -2-	25.04.
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	25.04.
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	24.04.
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million	24.04.
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline	24.04.
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	24.04.
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	24.04.
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	23.04.
Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	23.04.
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	22.04.
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.04.
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	22.04.
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice	22.04.
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.04.
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split	22.04.
Cidara Therapeutics Announces Reverse Stock Split	22.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cidara Therapeutics, Inc.

Aktien

A3D4A6

US1717572069

CDTX

Andere Sprachen

Filter